LNTH

Business Context and Reporting Period

This Form 8-K, dated January 27, 2025, reports a material definitive agreement entered into by Lantheus Holdings, Inc. (Lantheus) and its subsidiary, Lantheus Medical Imaging, Inc. The filing details the acquisition of Evergreen Theragnostics, Inc., a clinical-stage radiopharmaceutical company focused on Contract Development and Manufacturing (CDMO) services and proprietary drug discovery.

Key Financial Metrics and Transaction Terms

The transaction involves a statutory merger with the following financial structure:

• Upfront Consideration: $250 million in cash payable at closing.
• Milestone Payments: Up to $752.5 million in additional cash contingent on specific trigger events.
• Total Potential Consideration: Up to $1,002.5 million.
• Reverse Termination Fee: $10 million payable to Evergreen if Lantheus fails to obtain certain regulatory approvals.
• Bridge Financing: Lantheus agreed to provide up to $18 million in unsecured loans to Evergreen.

The filing does not provide specific revenue, profit, cash flow, or debt metrics for Lantheus or Evergreen for the current period, as this is a transaction announcement rather than a periodic financial report.

Material Changes and Outlook

Lantheus reaffirmed its financial guidance for the year ended December 31, 2024, as previously issued on November 6, 2024. The merger is expected to close in the second half of 2025, subject to customary closing conditions including regulatory approvals (e.g., Hart-Scott-Rodino Act) and the transfer of licenses. Post-closing, Lantheus commits to using commercially reasonable efforts to seek regulatory approval and commercialize Evergreen's OCTEVY^TM in the United States.

Risks and Contingencies

Management highlighted several risks that could materially affect the transaction and future results:

• Regulatory Approval: Failure to obtain necessary antitrust or regulatory clearances could lead to termination or the payment of the $10 million reverse termination fee.
• Integration Risks: Challenges in integrating Evergreen's business, diverting management attention, or realizing expected synergies.
• Product Development: Uncertainty regarding the clinical success and regulatory approval of Evergreen's product candidates, specifically OCTEVY^TM.
• Market Reaction: Potential decline in Lantheus' stock price if the acquisition benefits are not realized as anticipated.

Investor Verification Checklist

• Verify the status of regulatory approvals required for the merger, specifically under the Hart-Scott-Rodino Act.
• Review the specific "Milestone Trigger Events" in the Merger Agreement (Exhibit 2.1) to understand the conditions for the $752.5 million in contingent payments.
• Assess the clinical trial data and regulatory pathway for OCTEVY^TM to evaluate the likelihood of achieving commercialization milestones.
• Monitor Lantheus' cash position and liquidity to ensure capacity for the $250 million upfront payment and potential milestone obligations.
• Confirm the timeline for the expected second-half 2025 closing against the July 27, 2025, termination deadline and potential extensions.